FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914050470> ?p ?o ?g. }

• W2914050470 endingPage "742" @default.
• W2914050470 startingPage "735" @default.
• W2914050470 abstract "Background Systemic mammalian target of rapamycin (mTOR) inhibitors are currently used in many dermatologic indications. Their topical use is recent and poorly codified. Objective To provide an overview of the topical use of mTOR inhibitors in dermatologic conditions and evaluate their efficacy and safety. Methods A literature search was performed in January 2017. Reports of all studies investigating the use of topical mTOR inhibitors in any dermatology diseases were included. The exclusion criteria were systemic use and mucosal administration. Results We included 40 studies with a total of 262 patients. In all, 11 dermatologic conditions were found, the most frequent being angiofibromas linked to tuberous sclerosis complex (157 patients). Topical mTOR inhibitors were significantly more efficient than placebo for angiofibromas (relative risk, 2.52; 95% confidence interval, 1.27-5.00; I2 = 0%). The median concentration of sirolimus was 0.1%, with a median treatment duration of 12 weeks. Topical mTOR inhibitors were well tolerated, with only mild or moderate local side effects (mostly irritative) reported. Blood level of sirolimus was not detected in 90% of patients. Limitations High heterogeneity in most studies. Conclusion This systematic review supports the efficacy of topical sirolimus for angiofibromas linked to tuberous sclerosis complex, with only local side effects reported. Other indications require further research. Systemic mammalian target of rapamycin (mTOR) inhibitors are currently used in many dermatologic indications. Their topical use is recent and poorly codified. To provide an overview of the topical use of mTOR inhibitors in dermatologic conditions and evaluate their efficacy and safety. A literature search was performed in January 2017. Reports of all studies investigating the use of topical mTOR inhibitors in any dermatology diseases were included. The exclusion criteria were systemic use and mucosal administration. We included 40 studies with a total of 262 patients. In all, 11 dermatologic conditions were found, the most frequent being angiofibromas linked to tuberous sclerosis complex (157 patients). Topical mTOR inhibitors were significantly more efficient than placebo for angiofibromas (relative risk, 2.52; 95% confidence interval, 1.27-5.00; I2 = 0%). The median concentration of sirolimus was 0.1%, with a median treatment duration of 12 weeks. Topical mTOR inhibitors were well tolerated, with only mild or moderate local side effects (mostly irritative) reported. Blood level of sirolimus was not detected in 90% of patients. High heterogeneity in most studies. This systematic review supports the efficacy of topical sirolimus for angiofibromas linked to tuberous sclerosis complex, with only local side effects reported. Other indications require further research." @default.
• W2914050470 created "2019-02-21" @default.
• W2914050470 creator A5001564881 @default.
• W2914050470 creator A5003175013 @default.
• W2914050470 creator A5080398125 @default.
• W2914050470 creator A5090924104 @default.
• W2914050470 date "2019-03-01" @default.
• W2914050470 modified "2023-10-17" @default.
• W2914050470 title "Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis" @default.
• W2914050470 cites W1495661978 @default.
• W2914050470 cites W1502172390 @default.
• W2914050470 cites W1523325609 @default.
• W2914050470 cites W1589027390 @default.
• W2914050470 cites W1595617857 @default.
• W2914050470 cites W1694779947 @default.
• W2914050470 cites W1829835490 @default.
• W2914050470 cites W1842110414 @default.
• W2914050470 cites W1968268983 @default.
• W2914050470 cites W1969812978 @default.
• W2914050470 cites W1971083702 @default.
• W2914050470 cites W1975163688 @default.
• W2914050470 cites W1981400002 @default.
• W2914050470 cites W1990504226 @default.
• W2914050470 cites W1991024287 @default.
• W2914050470 cites W1995197723 @default.
• W2914050470 cites W2000239178 @default.
• W2914050470 cites W2013808979 @default.
• W2914050470 cites W2014087704 @default.
• W2914050470 cites W2019090765 @default.
• W2914050470 cites W2025617594 @default.
• W2914050470 cites W2043864528 @default.
• W2914050470 cites W2055920264 @default.
• W2914050470 cites W2072367016 @default.
• W2914050470 cites W2072984258 @default.
• W2914050470 cites W2077926379 @default.
• W2914050470 cites W2085928717 @default.
• W2914050470 cites W2113177344 @default.
• W2914050470 cites W2128628492 @default.
• W2914050470 cites W2136133717 @default.
• W2914050470 cites W2137844804 @default.
• W2914050470 cites W2140896288 @default.
• W2914050470 cites W2166552111 @default.
• W2914050470 cites W2252785867 @default.
• W2914050470 cites W2282181553 @default.
• W2914050470 cites W2412945327 @default.
• W2914050470 cites W2472661466 @default.
• W2914050470 cites W2521224743 @default.
• W2914050470 cites W2542703599 @default.
• W2914050470 cites W2551971072 @default.
• W2914050470 cites W2580353762 @default.
• W2914050470 cites W2587268912 @default.
• W2914050470 cites W2593816418 @default.
• W2914050470 cites W2595729262 @default.
• W2914050470 doi "https://doi.org/10.1016/j.jaad.2018.10.070" @default.
• W2914050470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30744877" @default.
• W2914050470 hasPublicationYear "2019" @default.
• W2914050470 type Work @default.
• W2914050470 sameAs 2914050470 @default.
• W2914050470 citedByCount "35" @default.
• W2914050470 countsByYear W29140504702019 @default.
• W2914050470 countsByYear W29140504702020 @default.
• W2914050470 countsByYear W29140504702021 @default.
• W2914050470 countsByYear W29140504702022 @default.
• W2914050470 countsByYear W29140504702023 @default.
• W2914050470 crossrefType "journal-article" @default.
• W2914050470 hasAuthorship W2914050470A5001564881 @default.
• W2914050470 hasAuthorship W2914050470A5003175013 @default.
• W2914050470 hasAuthorship W2914050470A5080398125 @default.
• W2914050470 hasAuthorship W2914050470A5090924104 @default.
• W2914050470 hasBestOaLocation W29140504701 @default.
• W2914050470 hasConcept C126322002 @default.
• W2914050470 hasConcept C142724271 @default.
• W2914050470 hasConcept C16005928 @default.
• W2914050470 hasConcept C183713625 @default.
• W2914050470 hasConcept C185592680 @default.
• W2914050470 hasConcept C190283241 @default.
• W2914050470 hasConcept C204787440 @default.
• W2914050470 hasConcept C27081682 @default.
• W2914050470 hasConcept C2777921159 @default.
• W2914050470 hasConcept C2778980267 @default.
• W2914050470 hasConcept C55493867 @default.
• W2914050470 hasConcept C71924100 @default.
• W2914050470 hasConcept C86554907 @default.
• W2914050470 hasConcept C98274493 @default.
• W2914050470 hasConceptScore W2914050470C126322002 @default.
• W2914050470 hasConceptScore W2914050470C142724271 @default.
• W2914050470 hasConceptScore W2914050470C16005928 @default.
• W2914050470 hasConceptScore W2914050470C183713625 @default.
• W2914050470 hasConceptScore W2914050470C185592680 @default.
• W2914050470 hasConceptScore W2914050470C190283241 @default.
• W2914050470 hasConceptScore W2914050470C204787440 @default.
• W2914050470 hasConceptScore W2914050470C27081682 @default.
• W2914050470 hasConceptScore W2914050470C2777921159 @default.
• W2914050470 hasConceptScore W2914050470C2778980267 @default.
• W2914050470 hasConceptScore W2914050470C55493867 @default.
• W2914050470 hasConceptScore W2914050470C71924100 @default.
• W2914050470 hasConceptScore W2914050470C86554907 @default.
• W2914050470 hasConceptScore W2914050470C98274493 @default.

• next